Oncolytics Biotech (ONCY) Revenue (2009 - 2020)
Oncolytics Biotech (ONCY) posted quarterly Revenue of $31.2 million for Q3 2020, up 91.85% year-over-year from $16.3 million in Q4 2019, and down 9.72% quarter-over-quarter from $34.6 million in Q2 2020.
Oncolytics Biotech (ONCY) Revenue (2009 - 2020) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Revenue for 7 consecutive years, with $31.2 million the latest figure, recorded in Q3 2020.
- In Q3 2020, Revenue rose 91.85% year-over-year to $31.2 million; the TTM figure through Sep 2020 stood at $116.7 million (down 100.0% YoY), while the FY2018 annual figure was $14865.0 billion, changed N/A from the prior year.
- Revenue fell to $31.2 million in Q3 2020 per ONCY's latest filing, from $34.6 million in the prior quarter.
- Across five years, Revenue topped out at $16461.0 billion in Q1 2019 and bottomed at $18150.0 in Q3 2018.
- Historically, Revenue has averaged $3189.6 billion across 5 years, with a median of $32.9 million in 2020.
- Annual changes were most pronounced in 2017 — Revenue jumped 80243123.99% — and 2020, when it plunged 100.0%.
- Oncolytics Biotech's Revenue stood at $710374.0 in 2016, then surged by 80243123.99% to $570.0 billion in 2017, then surged by 2507.77% to $14865.0 billion in 2018, then slumped by 100.0% to $16.3 million in 2019, then jumped by 91.85% to $31.2 million in 2020.
- Business Quant data shows ONCY's Revenue at $31.2 million in Q3 2020, $34.6 million in Q2 2020, and $34.6 million in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.20 Bn | 131.35 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 86.09 Bn | 78.10 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 59.04 Bn | 53.90 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 42.04 Bn | 36.94 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 1.29 Bn |
| 7 | BioNTech SE | 28.04 Bn | 9.65 Bn | 668.28 Mn | 1.06 Bn |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn | 425.49 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.50 Bn | - | 674.14 Mn |
| 10 | Oncolytics Biotech | 97.24 Mn | 97.24 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 31.24 Mn |
| Jun 30, 2020 | 34.60 Mn |
| Mar 31, 2020 | 34.55 Mn |
| Sep 30, 2019 | 16.29 Mn |
| Jun 30, 2019 | 15.30 Mn |
| Mar 31, 2019 | 16,461.00 Bn |
| Dec 31, 2018 | 14,865.00 Bn |
| Sep 30, 2018 | 18,150.00 |
| Jun 30, 2017 | 570.03 Bn |
| Jun 30, 2016 | 710,374.00 |
| Jun 30, 2010 | 310,000.00 |
| Dec 31, 2009 | 310,000.00 |
| Sep 30, 2009 | 10.24 Mn |
| Jun 30, 2009 | 12.76 Mn |
| Mar 31, 2009 | 9.80 Mn |